Core Viewpoint - Avanos Medical, Inc. reported a mixed performance in Q3 2024, with adjusted EPS showing a year-over-year increase, but revenues declining slightly, indicating challenges in certain product lines while maintaining strength in others [1][2][12]. Financial Performance - Adjusted EPS from continuing operations was 36 cents, a 20% increase year over year, meeting the Zacks Consensus Estimate [1] - Revenues totaled $170.4 million, down 0.5% year over year, missing the Zacks Consensus Estimate by 2.7% [2] - Organic sales increased by 1.1% year over year [2]. Segment Analysis - Pain Management and Recovery segment reported net revenues of $72.2 million, a decrease of 5.4% year over year [6] - Digestive Health segment saw net revenues of $98.2 million, improving by 3.4% year over year, with organic growth of almost 3% [6][7]. Margin Analysis - Gross profit fell by 2.7% to $92.9 million, with gross margin contracting by 130 basis points to 54.5% [8] - Selling and general expenses decreased by 5.6% to $74.3 million, while research and development expenses increased by 18% year over year to $7.2 million [8]. Financial Update - Cash and cash equivalents at the end of Q3 were $89 million, down from $92.2 million at the end of Q2 [10] - Total debt decreased to $162 million from $175.1 million at the end of Q2 [10]. Guidance - The company expects net sales for the full year 2024 to be in the range of $683-$688 million, below the Zacks Consensus Estimate of $695.1 million [11] - Adjusted EPS for 2024 is anticipated to be between $1.30 and $1.45, with the Zacks Consensus Estimate at $1.39 [11]. Market Performance - Avanos shares have declined by 17.1% year to date, contrasting with the industry growth of 5.4% and the S&P 500 Index gain of 22.5% [4].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-36440 AVANOS MEDICAL, INC. (Exact name of registrant as specified in its charter) Delaware 46-4987888 (Sta ...

Avanos Medical Inc. (NYSE:AVNS) Q3 2024 Results Conference Call October 30, 2024 9:00 AM ET Company Participants Scott Galovan - Vice President of Strategy & Corporate Development Gary Blackford - Chairman Michael Greiner - Senior VP, CFO & Chief Transformation Officer Conference Call Participants Kristen Stewart - CL King Danny Stauder - Citizens JMP Operator Good morning, ladies and gentlemen, and welcome to the Avanos Medical, Avanos Third Quarter 2024 Earnings Call. [Operator Instructions] This call is ...

Avanos Medical (AVNS) came out with quarterly earnings of $0.36 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.30 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical technology company would post earnings of $0.29 per share when it actually produced earnings of $0.34, delivering a surprise of 17.24%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Avanos Med ...

AVANOS Investor Contact: Michael Greiner Avanos Medical, Inc. 470-562-2692 Investor.Relations@Avanos.com Media Contact: Katrine Kubis Avanos Medical, Inc. CorporateCommunications@Avanos.com Avanos Medical, Inc. Announces Third Quarter 2024 Results, retirement of CEO ALPHARETTA, Ga., October 30, 2024/PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted "Joe has deci ...

ALPHARETTA, Ga., Oct. 30, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2024 financial results and announced the retirement of its CEO, Joe Woody. Gary Blackford, Avanos Board Chairman, noted, "Joe has decided to retire after leading Avanos for the past seven years. Joe has agreed to assist the Company in the transition of leadership, and will continue to consult with the Company through April of next year. Avanos is better positioned financially and organizationally to ...

ALPHARETTA, Ga., Oct. 23, 2024 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS) will webcast its conference call discussing financial results and business highlights for the third quarter 2024 on Wednesday, Oct. 30 at 9 a.m., ET. The company will issue a news release detailing its results before the market opens that same day.The conference call will be hosted by Joe Woody, chief executive officer, and Michael Greiner, senior vice president, chief financial officer, and chief transformation officer.To join ...

Avanos Medical (AVNS) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Of these, value investing is easily one of the most popular ways to find great stocks in any market environment. Value investors use tried-and-true metrics and fundamental analysis to find companies that they beli ...

Avanos Medical, Inc. (AVNS) is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism led by a solid fiscal second-quarter 2024 performance and continued focus on its research and development (R&D) are expected to contribute further. However, macroeconomic concerns and foreign exchange volatility persist.In the year-to-date period, this Zacks Rank #2 (Buy) stock has gained 3.7% compared with the 8.4% rise of the industry and 20% growth of the S&P 500 Composite.T ...